Baird Financial Group
SGMT icon

Baird Financial Group’s Sagimet Biosciences SGMT Stock Holding History

Baird Financial Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.4K Buy
+13,086
New +$72.9K ﹤0.01% 1816

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baird Financial Group's SGMT Position: Q1 2026 in Review

Baird Financial Group opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 13,086 shares worth $68.4K. The stake represents ﹤0.01% of the portfolio and ranks #1816 among its holdings.

88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Baird Financial Group held 13,086 shares of Sagimet Biosciences worth $68.4K as of Q1 2026.
  • Sagimet Biosciences was a new Baird Financial Group position in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Baird Financial Group's portfolio in Q1 2026, its #1816 holding.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.